PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
RPRX vs. JNJ
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RPRX and JNJ is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

RPRX vs. JNJ

Last updated May 31, 2025

Compare and contrast key facts about Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RPRX or JNJ.

Performance

RPRX vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

RPRX:

1.17

JNJ:

0.55

Sortino Ratio

RPRX:

1.83

JNJ:

0.89

Omega Ratio

RPRX:

1.24

JNJ:

1.12

Calmar Ratio

RPRX:

0.55

JNJ:

0.64

Martin Ratio

RPRX:

4.50

JNJ:

1.68

Ulcer Index

RPRX:

6.01%

JNJ:

6.54%

Daily Std Dev

RPRX:

24.41%

JNJ:

18.83%

Max Drawdown

RPRX:

-49.68%

JNJ:

-52.60%

Current Drawdown

RPRX:

-30.95%

JNJ:

-8.05%

Fundamentals

Market Cap

RPRX:

$18.35B

JNJ:

$369.52B

EPS

RPRX:

$2.45

JNJ:

$8.98

PE Ratio

RPRX:

13.32

JNJ:

17.10

PEG Ratio

RPRX:

2.92

JNJ:

1.04

PS Ratio

RPRX:

8.10

JNJ:

4.14

PB Ratio

RPRX:

2.06

JNJ:

4.73

Total Revenue (TTM)

RPRX:

$2.26B

JNJ:

$89.33B

Gross Profit (TTM)

RPRX:

$2.26B

JNJ:

$61.01B

EBITDA (TTM)

RPRX:

$2.33B

JNJ:

$34.70B

Returns By Period

In the year-to-date period, RPRX achieves a 30.61% return, which is significantly higher than JNJ's 9.11% return.

RPRX

YTD

30.61%

1M

0.85%

6M

24.98%

1Y

28.29%

3Y*

-4.75%

5Y*

N/A

10Y*

N/A

JNJ

YTD

9.11%

1M

0.15%

6M

1.79%

1Y

10.31%

3Y*

-1.81%

5Y*

3.76%

10Y*

7.44%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Royalty Pharma plc

Johnson & Johnson

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

RPRX vs. JNJ — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
RPRX
The Risk-Adjusted Performance Rank of RPRX is 8181
Overall Rank
The Sharpe Ratio Rank of RPRX is 8585
Sharpe Ratio Rank
The Sortino Ratio Rank of RPRX is 8282
Sortino Ratio Rank
The Omega Ratio Rank of RPRX is 8080
Omega Ratio Rank
The Calmar Ratio Rank of RPRX is 7474
Calmar Ratio Rank
The Martin Ratio Rank of RPRX is 8484
Martin Ratio Rank
JNJ
The Risk-Adjusted Performance Rank of JNJ is 6868
Overall Rank
The Sharpe Ratio Rank of JNJ is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of JNJ is 6262
Sortino Ratio Rank
The Omega Ratio Rank of JNJ is 6363
Omega Ratio Rank
The Calmar Ratio Rank of JNJ is 7676
Calmar Ratio Rank
The Martin Ratio Rank of JNJ is 7070
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RPRX vs. JNJ - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RPRX Sharpe Ratio is 1.17, which is higher than the JNJ Sharpe Ratio of 0.55. The chart below compares the historical Sharpe Ratios of RPRX and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

RPRX vs. JNJ - Dividend Comparison

RPRX's dividend yield for the trailing twelve months is around 2.62%, less than JNJ's 3.23% yield.

TTM20242023202220212020201920182017201620152014
RPRX
Royalty Pharma plc		2.62%3.29%2.85%1.92%1.71%0.60%0.00%0.00%0.00%0.00%0.00%0.00%
JNJ
Johnson & Johnson		3.23%3.40%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%2.64%

Drawdowns

RPRX vs. JNJ - Drawdown Comparison

The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum JNJ drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for RPRX and JNJ.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

RPRX vs. JNJ - Volatility Comparison

Royalty Pharma plc (RPRX) has a higher volatility of 7.62% compared to Johnson & Johnson (JNJ) at 6.09%. This indicates that RPRX's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

RPRX vs. JNJ - Financials Comparison

This section allows you to compare key financial metrics between Royalty Pharma plc and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.005.00B10.00B15.00B20.00B25.00B20212022202320242025
568.25M
21.89B
(RPRX) Total Revenue
(JNJ) Total Revenue
Values in USD except per share items

RPRX vs. JNJ - Profitability Comparison

The chart below illustrates the profitability comparison between Royalty Pharma plc and Johnson & Johnson over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.
Gross Margin
Operating Margin
Net Margin
Quarterly
Annual
0.0%20.0%40.0%60.0%80.0%100.0%20212022202320242025
100.0%
66.4%
(RPRX) Gross Margin
(JNJ) Gross Margin
RPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Royalty Pharma plc reported a gross profit of 568.25M and revenue of 568.25M. Therefore, the gross margin over that period was 100.0%.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported a gross profit of 14.54B and revenue of 21.89B. Therefore, the gross margin over that period was 66.4%.

RPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Royalty Pharma plc reported an operating income of 534.18M and revenue of 568.25M, resulting in an operating margin of 94.0%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported an operating income of 6.30B and revenue of 21.89B, resulting in an operating margin of 28.8%.

RPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Royalty Pharma plc reported a net income of 238.35M and revenue of 568.25M, resulting in a net margin of 41.9%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Johnson & Johnson reported a net income of 11.00B and revenue of 21.89B, resulting in a net margin of 50.2%.